Objectives: The challenges in managing Hidradenitis suppurativa(HS) and the substantial disease burden for patients and the health system have recently gained attention.
According to the VOICE project, a multinational survey among 1,299 participants, 45.9% of HS-patients are dissatisfied or very dissatisfied with care, even though they mainly received treatment according to current guidelines (mostly oral antibiotics, 85.6%).While HS was in the past mainly treated surgically in the stationary setting, it is now increasingly becoming relevant for outpatient care due to the increasing therapeutic options.
Materials / method: The literature was screened for all therapies approved for the indication of HS since the publication of the European guidelines in 2015. Moreover, all drug-option for HS currently undergoing phase-III-trials were identified from the database of clinicaltrials.gov
Results: A new device-based therapy option, combining intense pulsed light and radiofrequency, was approved for HS which shows good results in two randomized controlled trials and case reports and can be applied as long-term treatment. Clinicaltrials.gov showed that Secukinumab and Bimekizumab as well as Povorcitinib and Metformin are currently in the stage of phase-III trials. While results of the completed Bimekizumab trial are not published yet, the placebo-controlled trials on Secukinumab have recently been completed with HiSCR-response approximately 10% lower than that of Adalimumab.
Conclusion: The therapy repertoire for HS is currently subject to rapid development. Besides the expected future availability of additional biologics and small molecules, especially the device-based therapy option combining intense pulsed light and radiofrequency shows promising results mainly in the treatment of Hurley I and II. This enables doctors in outpatient care to design efficient individualized long-term treatment plans for their HS-patients.
利益冲突声明
您有否接受任何资金来支持研究这个主题?
否
您是否接受过关于这项研究的任何酬金或其他报酬?
否
你是否和任何与您的研究所涉及的药物,材料或工具有密切联系的实体存在财务关系?
否
你是否拥有或者您已经为您此研究中的工具,药物或材料申请任何专利?
否
这项工作没有任何直接或间接的资金支持。由作者自己承担责任。